Breast can­cer hope

Sunday Herald Sun - - News -

VI­O­LENT of­fend­ers are fight­ing to stay in Aus­tralia af­ter their visas have been can­celled, with al­most 70 launch­ing ap­peals against de­por­ta­tion.

The trend comes as new Depart­ment of Im­mi­gra­tion fig­ures show a record num­ber of visa can­cel­la­tions this year, with mur­der­ers, rapists and child pornog­ra­phy of­fend­ers among those sent pack­ing.

Un­der a sec­tion 501 amend­ment of the Mi­gra­tion Act, the fed­eral im­mi­gra­tion min­is­ter has the power to can­cel a visa on char­ac­ter grounds.

New fig­ures show there were 1284 visas can­celled in the year to July, in­clud­ing 156 in June alone — up from 983 last year and 580 in 2014-15.

New Zealan­ders made up the largest num­ber of 501 can­cel­la­tions, fol­lowed by visa hold­ers from the UK, Viet­nam, Su­dan and Fiji, Depart­ment of Im­mi­gra­tion fig­ures show.

Vi­o­lent as­sault con­vic­tions re­sulted in 258 for­eign­ers los­ing their right to re­main in Aus­tralia, with an­other 207 sent pack­ing af­ter en­gag­ing in se­ri­ous drug of­fences.

Child sex of­fences led to 75 visa can­cel­la­tions, while an­other 34 were an­nulled fol­low­ing rape and other sex of­fence charges. Mur­der charges led to 25 visa can­cel­la­tions, while 19 peo­ple were booted out af­ter be­ing con­victed of child pornog­ra­phy of­fences.

An­other 19 visas were can­celled fol­low­ing man­slaugh­ter con­vic­tions, and six for­eign­ers AUS­TRALIAN sci­en­tists have dis­cov­ered a mol­e­cule re­spon­si­ble for con­trol­ling a set of genes that, when “switched on”, can im­prove life ex­pectancy for the most com­mon form of breast can­cer by up to a decade.

Now they are hop­ing to take their re­search one step fur­ther by work­ing with a phar­ma­ceu­ti­cal com­pany to de­velop a drug to tar­get the mol­e­cule, called G9a, af­ter find­ing a sim­i­lar drug halved the size of tu­mours in mice.

QIMR Berghofer Med­i­cal Re­search In­sti­tute’s Ja­son Lee said the G9a mol­e­cule con­trolled a set of genes that, when “switched on”, could ex­tend the life of pa­tients with oe­stro­gen-re­cep­tor-pos­i­tive (ER+) type breast can­cer by be­tween eight and 10 years.

This sub­type is the most com­mon form of the can­cer.

Dr Lee said the re­search group also found that an avail­able drug that tar­gets G9a could be used to slow tu­mour growth by more than half.

He said the drug used, a type of epi­ge­netic en­zyme mod­i­fy­ing in­hibitor, was un­suit­able for hu­man tri­als, but QIMR Berghofer was work­ing with a phar­ma­ceu­ti­cal com­pany to hope­fully THE Pen­tagon has con­firmed US forces have killed the head of Is­lamic State in Afghanistan, Abu Sayed, in a strike on the group’s head­quar­ters in Ku­nar prov­ince.

Pen­tagon spokes­woman Dana White said the raid last Tues­day had killed other IS mem­bers and would “sig­nif­i­cantly dis­rupt the ter­ror group’s plans to ex­pand its pres­ence in Afghanistan”.

Sayed was the leader of lost their visas af­ter en­gag­ing in kid­nap­ping.

Peo­ple who have had their visas can­celled have 28 days to ap­peal the de­ci­sion.

Among the 66 ap­peals lodged in the Ad­min­is­tra­tive Ap­peals Tri­bunal this year was that of a New Zealand-born man with 21 theft and drug con­vic­tions from of­fences con­ducted in his home­land. ISIS-Kho­rasan, the ter­ror group’s Afghanistan af­fil­i­ate.

Sec­re­tary of De­fense James Mat­tis said the death of a leader like Sayed “sets them back for a day, a week, a month … It is ob­vi­ously a vic­tory on our side in terms of set­ting them back, it’s the right di­rec­tion”.

US Forces Afghanistan Com­man­der Gen. John Ni­chol­son said: “Abu Sayed is the third ISIS-K emir we have killed in the last year

Upon ar­riv­ing in Aus­tralia in 2013, the man con­tin­ued his crime spree.

The man was also con­victed of breach­ing an ap­pre­hended vi­o­lence or­der 36 times, which he blamed on at­tempts to see his son.

Tri­bunal deputy pres­i­dent Den­nis Cow­droy QC said it was clear the man posed an on­go­ing risk to the com­mu­nity. cre­ate a “more sta­ble” ver­sion. “We have ac­tu­ally come up with lead com­pounds that seem to work very well in in­duc­ing cell death in breast can­cer cells,” Dr Lee said.

There was also ev­i­dence the drug could be use­ful in treat­ing other kinds of breast can­cer in com­bi­na­tion with tra­di­tional ther­a­pies such as chemo­ther­apy.

Mother of two Natalie Guardala was first di­ag­nosed with earlystage breast can­cer in 2010, and suf­fered a re­cur­rence four years later while 30 weeks’ preg­nant with her sec­ond child.

She is now in re­mis­sion, but the ex­pe­ri­ence was so life-chang­ing for Ms Guardala — whose mother has also sur­vived breast can­cer — it prompted her to give up her job as a lawyer for a ca­reer with QIMR Berghofer.

She wel­comed the dis­cov­ery of the genes, which Dr Lee said were pre­dic­tors of whether a pa­tient was likely to ex­pe­ri­ence a can­cer re­cur­rence.

“Re­cur­rence is the great­est fear of any breast can­cer sur­vivor. It’s some­thing I live with ev­ery day,” Ms Guardala said. kara.vick­ery@news.com.au and we will con­tinue un­til they are an­ni­hi­lated. There is no safe haven for ISIS-K in Afghanistan.”

Afghan and US forces launched a counter ISIS-K of­fen­sive in early March, and the US hopes to push the ter­ror group out of Afghanistan by the end of this year.

The news comes amid con­flict­ing re­ports about the death of Is­lamic State leader Abu Bakr al-Bagh­dadi.

US kills IS Afghanistan leader

LEAD­ING Melbourne model El­yse Knowles has swapped stilet­tos for steel-capped boots and swim­suits for tradie shorts as part of her

makeover. Tomboy Knowles and her part­ner, Josh Barker, are among the con­tes­tants who are ren­o­vat­ing five weath­er­board houses that have been moved to

site in El­stern­wick. “It is def­i­nitely not the glam­orous life,” she said.

“I’m happy to be a tomboy, I like get­ting my hands dirty.

“We have been liv­ing out of a porta-toi­let, have a portable shower which is cen­time­tres deep in mud when you first get in there, you trek across the back of the prop­erty in your boots when you first get out of the shower, there is no high life here.

“But I def­i­nitely don’t care, at all, what I look like.”

Knowles and Barker joined not long af­ter ren­o­vat­ing their own home.

“It has se­ri­ously been the most crazy ex­pe­ri­ence, I have never worked so hard in my life,” she said.

“We are happy that we can have this ad­ven­ture to­gether. I think it has made our re­la­tion­ship stronger.”

While Knowles is look­ing for­ward to a break af­ter fin­ish­ing prop­erty, car­pen­ter Barker has other ideas.

“Josh just told me as soon as we fin­ish here we need to buy a house and do it again — he has all these ideas,” she said. Pic­ture: DAVID CAIRD

world­wide, with $119 mil­lion, while Me­tal­lica ($112 mil­lion) and Depeche Mode ($87 mil­lion) rounded out the top five.

Adele was the top­per­form­ing fe­male, at No.7 glob­ally ($75 mil­lion), right be­hind Red Hot Chili Pep­pers ($87 mil­lion).

Over­all, world tour­ing was down $12.8 mil­lion from 2016, driven by a slight drop in ticket prices. Axl Rose, of Guns N’ Roses.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.